{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:02:23Z","timestamp":1760781743293,"version":"build-2065373602"},"reference-count":7,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T00:00:00Z","timestamp":1357862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:p>Luteinizing hormone (LH) is physiologically produced by the anterior pituitary gland. Male athletes may use pharmaceutical LH for doping since it increases the production of testosterone by testes. This hormone is thus on the World Anti\u2010Doping Agency (WADA) list of substances prohibited for males. Anti\u2010doping laboratories perform the assay of this hormone in urine and report abnormally elevated results. We observed a highly significant prevalence of abnormal results in samples taken after a boxing match. Comparison of the descriptive statistics for 426 LH values observed in boxing and other sports showed significant differences. An experimental study comparing urinary LH levels in 17 boxers before and after a match demonstrated a clear increase after the match. The same observation was made for urinary follicle stimulating hormone (FSH) in all of the eight boxers tested for this other pituitary gonadotropin. These observations have consequences for anti\u2010doping controls, as the reference range for urinary LH levels must take into account the specificities of boxers. They also suggest consequences for the health of boxers. Although to our knowledge such observations have never been described, other pituitary disorders have been reported. Our results deserve further investigation from a medical point of view. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.1452","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T11:49:50Z","timestamp":1357904990000},"page":"277-279","source":"Crossref","is-referenced-by-count":5,"title":["The problem of anti\u2010doping control of luteinizing hormone in boxing"],"prefix":"10.1002","volume":"5","author":[{"given":"Jean Louis","family":"Llouquet","sequence":"first","affiliation":[{"name":"French Boxing Federation  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Crepin","sequence":"additional","affiliation":[{"name":"Agence fran\u00e7aise de lutte contre le dopage \u2010 D\u00e9partement des analyses  143 avenue Roger Salengro 92290 Ch\u00e2tenay\u2010Malabry France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Lasne","sequence":"additional","affiliation":[{"name":"Agence fran\u00e7aise de lutte contre le dopage \u2010 D\u00e9partement des analyses  143 avenue Roger Salengro 92290 Ch\u00e2tenay\u2010Malabry France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,11]]},"reference":[{"key":"e_1_2_4_2_1","unstructured":"WADA prohibited list. Available at:http:\/\/www.wada\u2010ama.org\/Documents\/World_Anti\u2010Doping_Program\/WADP\u2010Prohibited\u2010list\/2012\/WADA_Prohibited_List_2012_EN.pdf[3 January 2013]."},{"key":"e_1_2_4_3_1","first-page":"259","volume-title":"William Textbook of Endocrinology","author":"Griffin J.E.","year":"1985"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2009.11.008"},{"key":"e_1_2_4_5_1","first-page":"835","article-title":"Boxing\u2010acute complications and late sequelae: From concussion to dementia","volume":"107","author":"F\u00f6rstl H.","year":"2010","journal-title":"Dtsch. Arztebl. Int."},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345299"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-11-200806030-00005"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-1024"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.1452","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.1452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:40:52Z","timestamp":1760384452000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.1452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,11]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1002\/dta.1452"],"URL":"https:\/\/doi.org\/10.1002\/dta.1452","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"type":"print","value":"1942-7603"},{"type":"electronic","value":"1942-7611"}],"subject":[],"published":{"date-parts":[[2013,1,11]]}}}